Form 8-K Aquestive Therapeutics, For: Mar 14
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Aquestive Therapeutics (AQST) PT Lowered to $21 at BMO Capital
March 15, 2019 6:51 AM EDTBMO Capital analyst Gary Nachman lowered the price target on Aquestive Therapeutics (NASDAQ: AQST) to $21.00 (from $24.00) while maintaining a Outperform rating following relatively in-line 4Q18 results.
guidance is appropriately conservative and should be very achievablemanagement sounded confident in several potential nondilutive financing options... More
